NEWS
Cell Therapy Product Development Expert Dr. Panos Chrysanthopoulos Joins Morphocell Technologies as Chief Development Officer
Montreal, QC, July 24, 2023 – Morphocell Technologies Inc., a leading start-up in the field of regenerative medicine, is excited to announce the appointment of Dr. Panos Chrysanthopoulos as its new Chief Development Officer.
Dr. Chrysanthopoulos is a highly respected leader in Cell Therapeutic Product Development and holds a PhD in Biomedical Engineering from The University of Queensland. With an extensive research background in Systems Biology dating back to 2005, he brings a deep understanding of advanced technologies to the forefront of therapeutic innovation. His expertise lies in the development of cutting-edge cell and gene therapies, translating early-stage discoveries into clinically relevant manufacturing processes and analytics.
With a strong focus on Quality by Design (QbD) principles, he has successfully built robust CMC strategies for comprehensive PSC-derived and CAR-T cell therapies. Dr. Chrysanthopoulos takes great pride in his experience of building and leading world-class process and analytical development teams. In his role, he will lead the Company's product development efforts and oversee Technical Operations, ensuring a scalable and sustainable product pipeline.
"I am thrilled and honored to join Morphocell’s outstanding leadership team, known for its technical excellence and firm commitment to pioneering groundbreaking solutions in liver disease treatment," said Dr. Chrysanthopoulos. "Together, driven by our shared vision to enhance patients' lives, we will leverage our collective expertise to develop groundbreaking therapies, setting new benchmarks in the field of regenerative medicine. I am looking forward to contributing towards the development and commercialization of world-class cell therapeutics that will revolutionize patient care."
Dr. Massimiliano Paganelli, co-founder and CEO of Morphocell Technologies, said, "We're delighted to welcome Dr. Chrysanthopoulos to our team. His dedication to fostering a culture of excellence, continuous improvement, and innovation aligns with our values and mission. His addition to our leadership team significantly strengthens our capabilities, driving our efforts to advance liver disease treatments."
About Morphocell Technologies Inc.
Morphocell Technologies is a Montreal-based regenerative medicine company focused on the development and commercialization of stem cell-derived tissue and organ replacement therapies. Its iPSC-derived platform technology has a large pipeline potential touching different organ deficiencies, with severe liver disease being the initial focus. Morphocell prides itself on its culture of innovation, technical excellence, and commitment to improving patients' lives.
Media Contact:
Zaynah Ibrahim
+ 1 (514) 373-6444 ext. 106